Solara Active Pharma Sciences financials

·Pharma & HealthChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹417cr+33.1% on Q2 FY26
Net profit
₹28.5cr−₹10.1 cr in Q2 FY26
EBITDA margin
18.4%+7.3 pts on Q2 FY26
EPS
₹5.92−₹2.36 in Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue417314+33.1%
EBITDA76.834.7+121.2%
EBITDA margin18.4%11.1%+7.3 pts
Profit before tax28.5−10.1—
Net profit28.5−10.1—
EPS₹5.92−₹2.36—

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹417 crNet profit₹28.5 crNet margin6.8%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2,910————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
25.17.54.08.48.7
2.72.72.72.92.2
6656657761,0001,001
3,552————
1,5351,3691,2841,2891,444
—+6.6%−0.4%−10.7%—
234187206−95.2134
15.2%13.6%16.1%−7.4%9.3%
12987.1107−19922.7
36.9−7.40.5−567−22.2
2.4%−0.5%0.0%−44.0%−1.5%
₹8.30−₹1.66₹0.12−₹127.47−₹4.98
—−1,472.2%+100.1%−2,459.3%—
—153213109156
—−52.8−39.9−41.1−111
10010017367.844.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SOLARA₹653.80

Solara Active Pharma Sciences Limited

· Pharma & Health
₹ CrorePeersINDSWFTLABDCALSMSPHARMAHIKALPANACEABIOSAIPARENTINDOCOUNICHEMLABMcap ₹2,910 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————2,910.1
- Cash, Equiv & ST Investments8.78.44.07.525.1
+ Minority Interest2.22.92.72.72.7
+ Total Debt1,001.2999.9776.1664.5664.5
Enterprise Value————3,552.2
Revenue1,443.81,288.91,283.81,369.01,535.2
Growth %, YoY—-10.7-0.4+6.6—
EBITDA133.9-95.2206.3186.8233.8
Margin %9.27-7.3816.0713.6415.23
EBIT22.7-198.5107.087.1128.9
Net Income-22.2-567.00.5-7.436.9
Margin %-1.54-43.990.04-0.542.41
EPS, Adj (current shares)-4.98-127.470.12-1.668.30
Growth %, YoY—-2,459.3+100.1-1,472.2—
Cash from Operations156.3108.9212.8152.9—
Capital Expenditures-111.3-41.1-39.9-52.8—
Free Cash Flow44.967.8172.9100.1100.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Solara Active Pharma Sciences financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Solara Active Pharma Sciences (NSE: SOLARA) had a market capitalisation of ₹3,156 crore at the 29 October 2026 close (₹655.25 a share), a PE ratio of 85.4 on the last four quarters' profit and a price-to-book ratio of 2.20. In FY26 its consolidated net loss was ₹7.4 crore on revenue of ₹1,369 crore; in Q2 FY27 (July–September 2026) it was ₹28.5 crore. Its debt-to-equity ratio was 0.40 on 30 September 2026. Promoters held 41.93% of the shares on 30 September 2026.

Share price used
₹655.25 · 29 October 2026 close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

Solara Active Pharma Sciences at a glance · consolidated

Market cap
₹3,156 Crat ₹655.25 · 29 Oct close
PE ratio (last 4 quarters)
85.4
Price to book (PB)
2.20book value ₹298.19 a share
ROE (FY26)
−0.6%−0.7 pts vs FY25ROCE 6.4%
Debt to equity
0.40net debt ₹499 Cr
Promoter holding
41.93%unchanged vs 30 Jun 202630 September 2026
Net worth
₹1,436 Cr+14.4% vs 30 Sep 202530 September 2026
Free cash flow (FY26)
₹100 Cr−42.1% vs FY25
EPS (FY26)
−₹1.68

Questions

What is the Solara Active Pharma Sciences PE ratio today?

Solara Active Pharma Sciences' PE ratio is 85.4 at the 29 October 2026 close (₹655.25 a share): a market capitalisation of ₹3,156 crore divided by consolidated net profit of ₹36.9 crore over the last four quarters (Q3 FY26 to Q2 FY27). These four quarters include net exceptional items of −₹10.4 crore (one-off charges reported separately), so the ratio on recurring profit would differ.

What is the Solara Active Pharma Sciences PB ratio (price to book value)?

Solara Active Pharma Sciences' price-to-book (PB) ratio is 2.20 at the 29 October 2026 close: a market capitalisation of ₹3,156 crore divided by shareholders' equity (book value) of ₹1,436 crore on 30 September 2026. That is a book value of ₹298.19 per share against a share price of ₹655.25.

What is the Solara Active Pharma Sciences ROE and ROCE?

In FY26, Solara Active Pharma Sciences' return on equity (ROE) was −0.6% and its return on capital employed (ROCE) was 6.4%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 0.1% and ROCE 8.9%.

What is the Solara Active Pharma Sciences market cap?

Solara Active Pharma Sciences' market capitalisation was ₹3,156 crore at the 29 October 2026 close: 4.82 crore shares at ₹655.25 each.

Is Solara Active Pharma Sciences debt free?

No. Solara Active Pharma Sciences had borrowings of ₹570 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.40. Its cash and current investments were ₹70.9 crore, so its net debt was ₹499 crore.

What is the Solara Active Pharma Sciences debt to equity ratio?

Solara Active Pharma Sciences' debt-to-equity ratio was 0.40 on 30 September 2026: borrowings of ₹570 crore against total equity of ₹1,439 crore. A year earlier, on 30 September 2025, it was 0.50.

What is the Solara Active Pharma Sciences net worth?

Solara Active Pharma Sciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹1,436 crore on 30 September 2026, up 14.4% from ₹1,255 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹3,156 crore at the 29 October 2026 close.

What is the Solara Active Pharma Sciences book value per share?

Solara Active Pharma Sciences' book value per share was ₹298.19 on 30 September 2026: shareholders' equity of ₹1,436 crore divided by the 4.82 crore shares in issue, up 5.7% from ₹282.17 a year earlier. The share price at the 29 October 2026 close was ₹655.25.

What is the Solara Active Pharma Sciences promoter holding?

Promoters held 41.93% of Solara Active Pharma Sciences on 30 September 2026, unchanged from the previous quarter and down 0.08 percentage points from 42.01% a year earlier, according to the shareholding pattern filed with NSE.

What is the Solara Active Pharma Sciences EPS?

Solara Active Pharma Sciences' basic earnings per share (EPS) were −₹1.68 in FY26. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹7.66.

What is the Solara Active Pharma Sciences free cash flow?

In FY26, Solara Active Pharma Sciences generated ₹153 crore of cash from operations and spent ₹52.8 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹100 crore. In FY25 it was ₹173 crore.

What is the Solara Active Pharma Sciences revenue and profit in FY26?

In FY26 (April 2025–March 2026), Solara Active Pharma Sciences' consolidated net loss was ₹7.4 crore, against a profit of ₹54 lakh in FY25, on revenue from operations of ₹1,369 crore (up 6.6%).

What is the Solara Active Pharma Sciences shareholding pattern?

On 30 September 2026, Solara Active Pharma Sciences' shares were held by promoters 41.93%, foreign portfolio investors (FII/FPI) 10.71%, domestic institutions (DII) 3.89% (including mutual funds at 0.87%) and retail and other non-institutional investors 43.46%. Over the year, FII holding was down 2.87 percentage points from 13.58% and DII holding was up 1.20 percentage points from 2.69%.

What are the Solara Active Pharma Sciences latest quarterly results?

Solara Active Pharma Sciences' latest results are for Q2 FY27 (July–September 2026), filed on 16 October 2026: consolidated net profit ₹28.5 crore, against a loss of ₹10.1 crore in Q2 FY26; revenue from operations ₹417 crore, up 33.1% year on year.

Solara Active Pharma Sciences vs Ind-Swift Laboratories: how do they compare?

In FY26, Solara Active Pharma Sciences earned net profit of ₹7.4 crore on revenue of ₹1,369 crore, against ₹41.4 crore on ₹641 crore for Ind-Swift Laboratories. Solara Active Pharma Sciences' operating margin was 6.4% (Ind-Swift Laboratories 2.3%) and its return on equity −0.6% (Ind-Swift Laboratories 3.2%). At the 29 October 2026 close, Solara Active Pharma Sciences' market capitalisation was ₹3,156 crore against ₹3,564 crore for Ind-Swift Laboratories.

When are the Solara Active Pharma Sciences next results?

Solara Active Pharma Sciences has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

How does Solara Active Pharma Sciences compare with its peers?

On FY26 consolidated figures, against Ind-Swift Laboratories, Dishman Carbogen Amcis and SMS Pharmaceuticals: Solara Active Pharma Sciences' operating margin of 6.4% is the third highest of the four (Ind-Swift Laboratories 2.3%, Dishman Carbogen Amcis 7.7%, SMS Pharmaceuticals 14.8%; peer average 8.3%); its return on equity of −0.6% is the lowest of the four (Ind-Swift Laboratories 3.2%, Dishman Carbogen Amcis 1.6%, SMS Pharmaceuticals 14.3%; peer average 6.4%); its revenue growth over three years of −1.8% a year is the third highest of the four (Ind-Swift Laboratories −19.0% a year, Dishman Carbogen Amcis 6.7% a year, SMS Pharmaceuticals 19.3% a year; peer average 2.3% a year).

Where do these Solara Active Pharma Sciences figures come from?

From Solara Active Pharma Sciences' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.